Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001658964 | SCV001874225 | uncertain significance | not provided | 2021-07-06 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 27535533) |
Ambry Genetics | RCV002538552 | SCV003658954 | uncertain significance | Inborn genetic diseases | 2021-07-14 | criteria provided, single submitter | clinical testing | The c.4949C>T (p.S1650F) alteration is located in exon 42 (coding exon 42) of the OTOGL gene. This alteration results from a C to T substitution at nucleotide position 4949, causing the serine (S) at amino acid position 1650 to be replaced by a phenylalanine (F). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV001658964 | SCV004253354 | likely benign | not provided | 2024-10-24 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV001658964 | SCV005191918 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Prevention |
RCV004752034 | SCV005352548 | likely benign | OTOGL-related disorder | 2024-03-14 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |